OXB - OXFORD BIOMEDICA - Share Chat
Oxford Biomedica is a leading UK-based gene and cell therapy company, specialising in the development and manufacturing of lentiviral vectors. Leveraging its proprietary LentiVector® platform, the company operates as a critical Contract Development and Manufacturing Organisation (CDMO) for advanced therapy medicinal products (ATMPs).
It supports a diverse range of biopharmaceutical clients, providing essential components and expertise for gene therapy development and commercial supply. Notable collaborations include the supply of lentiviral vectors for Novartis’s CAR-T therapy, Kymriah, and its significant role in manufacturing the Oxford/AstraZeneca COVID-19 vaccine. OXB is strategically positioned at the forefront of the rapidly expanding gene therapy market, pursuing both partnered programmes and its own therapeutic pipeline.
Chat about OXFORD BIOMEDICA
Oxford Biomedica (OXB) – the UK's gene therapy powerhouse. Recent Q1 results and partnership updates have certainly kept things interesting. What's your outlook here? Are they undervalued given their LentiVector platform, or does the sector still face too many headwinds?